Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oklahoma Healthcare Wire.
Press releases published on June 12, 2025
MedRisk Welcomes Satish Narayanan as Chief Data Officer, Expanding Data and AI Capabilities
GlobeNewswire
·
June 12, 2025
KING OF PRUSSIA, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- MedRisk, a leading managed care organization focused on improving recovery and cost outcomes in casualty claims, announced today the appointment of Satish Narayanan as Chief Data Officer (“CDO”). In …
Gavin Gassen, M.D. Brings His Expertise to ENT and Allergy Associates’ Poughkeepsie Office
GlobeNewswire
·
June 12, 2025
Tarrytown, New York, June 12, 2025 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA), the largest ear, nose, throat, allergy, and audiology practice in the country, is proud to welcome Gavin M. Gassen, M.D., a board-certified Otolaryngologist and …
Levicept to Present Further Analysis from Phase II Trial of Novel Neurotrophin-3 Inhibitor, LEVI-04, at EULAR
GlobeNewswire
·
June 12, 2025
Significant and clinically meaningful improvement in pain, function, and other outcomes in people with knee osteoarthritis Rapid onset of action observed Improvement in function out of proportion to pain-relieving effects First-in-class novel biologic …
Enterome raises $19 million to fund clinical development of its OncoMimics™ immunotherapy to treat Follicular Lymphoma
GlobeNewswire
·
June 12, 2025
Proceeds to fund Phase 1/2 trial of EO2463 OncoMimics™, as a monotherapy or in combination, to treat multiple forms of indolent non-Hodgkin lymphoma (iNHL) $9 million from new investor The Institute for Follicular Lymphoma Innovation (IFLI) $10 million …
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
GlobeNewswire
·
June 12, 2025
Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports development of a novel, in vivo approach to …
SNIPR BIOME Announces First Patient Dosed in its Phase 1b Clinical Trial of SNIPR001 in Patients with Hematological Cancer
GlobeNewswire
·
June 12, 2025
COPENHAGEN, Denmark, June 12, 2025 (GLOBE NEWSWIRE) -- SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for microbial gene therapy, today announced that the first patient has been dosed in its …
Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress
GlobeNewswire
·
June 12, 2025
Median duration of response in FELIX study now 42.6 months after an additional 11 months of follow up More than half of patients still in remission at 24 months 38% of ongoing responders did not receive any subsequent therapy by month 33 Results suggest a …
Diagonal Therapeutics to Present New Preclinical Data Demonstrating Disease-Modifying Potential of Receptor Clustering Antibody Approach in HHT at EHA 2025 Congress
GlobeNewswire
·
June 12, 2025
Results demonstrate potential of Company’s clustering antibody approach to address key challenges in HHT disease manifestations: restoring ALK1-mediated cellular signaling, preventing and reversing arteriovenous malformations, and preventing HHT-associated …
AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036
GlobeNewswire
·
June 12, 2025
PRESS RELEASE AB SCIENCE ANNOUNCES ISSUANCE OF A CANADIAN PATENT PROTECTING THE COMPOSITION OF MATTER OF AB8939, INCLUDING ITS USE IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML), WITH PROTECTION UNTIL 2036 THIS PATENT COMPLETES INTELLECTUAL PROPERTY …
AB Science annonce la délivrance d’un brevet canadien protégeant la composition de matière d’AB8939, y compris son utilisation dans le traitement de la leucémie myéloide aigue, avec une protection jusqu’à 2036
GlobeNewswire
·
June 12, 2025
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE LA DÉLIVRANCE D'UN BREVET CANADIEN PROTÉGEANT LA COMPOSITION DE MATIERE D’AB8939, Y COMPRIS SON UTILISATION DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË (LMA), AVEC UNE PROTECTION JUSQU'EN 2036 CE BREVET COMPLÈTE …
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
GlobeNewswire
·
June 12, 2025
Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activity DZP showed consistent improvements in fatigue, a common and debilitating symptom of systemic lupus …
AstriVax Therapeutics Further Strengthens Team with the Appointment of Dieter Weinand as New Chair of the Board of Directors
GlobeNewswire
·
June 12, 2025
US-based Dieter Weinand is the former CEO of Bayer Pharma with more than 25 years of experience as a senior business leader in the pharmaceutical industry The appointment comes as AstriVax Therapeutics matures as a clinical stage immunotherapy company with …
UK leads G7 countries in addressing child sexual violence, but ODA cuts are hurting progress
GlobeNewswire
·
June 12, 2025
LONDON, June 12, 2025 (GLOBE NEWSWIRE) -- The UK is the best performer among G7 countries in addressing child sexual violence and is spearheading international efforts to end online sexual violence, but cuts in Official Development Assistance (ODA) are …
New trailer type gets strong underride guard
GlobeNewswire
·
June 12, 2025
ARLINGTON, Va., June 12, 2025 (GLOBE NEWSWIRE) -- A Stoughton chassis designed for container transport is the first of its kind to qualify for the Insurance Institute for Highway Safety’s TOUGHGUARD award for superior underride protection. Wisconsin-based …
Nusano Announces Breakthrough HALEU Program Expected to Produce Up to 350 Metric Tons of Fuel Annually for Advanced Nuclear Reactors
GlobeNewswire
·
June 12, 2025
Reservations available now, commercial production deliveries begin Q1 2027 Proprietary process with reduced environmental impacts Efficient domestic supply chain needed to support projected growth in energy demand from increased electrification and energy- …
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
GlobeNewswire
·
June 12, 2025
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) …